Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey

被引:8
|
作者
Orbai, Ana-Maria [1 ]
Birt, Julie A. [2 ]
Holdsworth, Elizabeth A. [3 ]
Booth, Nicola [3 ]
Malatestinic, William N. [2 ]
Sprabery, Aubrey T. [2 ]
Reginato, Anthony M. [4 ,5 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Adelphi Real World, Bollington, England
[4] Brown Univ, Warren Alpert Med Sch, Div Rheumatol, Providence, RI 02912 USA
[5] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA
关键词
Patient-reported outcome; PROs; Psoriatic arthritis; Real-world evidence; Satisfaction; CLINICAL CHARACTERISTICS; DISEASE; COHORT; RECOMMENDATIONS; QUESTIONNAIRE; PREVALENCE; REGISTRY; EUROQOL;
D O I
10.1007/s40744-020-00242-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Enthesitis is a core outcome domain assessed in psoriatic arthritis (PsA) clinical trials. Limited evidence describes the impact of enthesitis on patient-reported outcomes (PROs) and physician satisfaction with current treatment options. The objective of this analysis is to characterize the impact of enthesitis on PROs and physician satisfaction with currently available treatment in clinical practice settings. Methods Cross-sectional survey of rheumatologists, dermatologists, and their consulting patients with PsA in Australia, Canada, European Union (EU5), and the USA conducted in 2018. Physicians assessed current presence and severity of enthesitis, overall disease severity, other symptoms experienced, and their satisfaction with the current treatment. PsA participant self-reported data included current pain level, EQ5D, Psoriatic Arthritis Impact of Disease (PsAID12), Health Assessment Questionnaire Disability Index (HAQ-DI), and Work Productivity and Activity Impairment Index (WPAI-SHP). Bivariate descriptive analyses were conducted to describe features and outcomes in participants with and without enthesitis. Results Rheumatologists (454) and dermatologists (238) provided information for 3157 participants with PsA. Mean participant age was 49.2 years, and 45.9% were female. Enthesitis was present currently in 6.5% (205) of participants with PsA. Those with enthesitis had worse overall disease severity compared to those without enthesitis (12.2% vs 2.2% severe) and had more extraarticular manifestations, including nail psoriasis, dactylitis, and sacroiliitis. Enthesitis was associated with more pain, worse quality of life (QoL), increased disability, and a negative impact on work. Participants with enthesitis had higher NSAIDs and opioid pain medication use but similar biologic use. Physicians were significantly less satisfied with current PsA treatment in participants with enthesitis versus without enthesitis. Conclusions Participants with psoriatic arthritis with enthesitis experienced significantly higher disease burden than those without enthesitis but were not more likely to receive advanced therapies. Physicians were significantly more dissatisfied with treatment in patients with enthesitis than in those without it.
引用
收藏
页码:937 / 948
页数:12
相关论文
共 50 条
  • [21] IMPACT OF PSORIATIC ARTHRITIS ON PATIENT-REPORTED OUTCOMES IN 5 EUROPEAN UNION COUNTRIES
    Gottlieb, A. B.
    Gratacos, J.
    Dikranian, A.
    Fallon, L.
    Emir, B.
    Smith, T.
    Aikman, L.
    Chen, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 670 - 671
  • [22] The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review
    Canete, Juan D.
    Pinto Tasende, Jose Antonio
    Rebollo Laserna, Francisco Jose
    Gomez Castro, Susana
    Queiro, Ruben
    RHEUMATOLOGY AND THERAPY, 2020, 7 (02) : 237 - 257
  • [23] The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review
    Juan D. Cañete
    Jose Antonio Pinto Tasende
    Francisco José Rebollo Laserna
    Susana Gómez Castro
    Rubén Queiro
    Rheumatology and Therapy, 2020, 7 : 237 - 257
  • [24] Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
    Mease, Philip J.
    Karki, Chitra
    Palmer, Jacqueline B.
    Etzel, Carol J.
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Malley, Wendi
    Herrera, Vivian
    Tran, Melody
    Greenberg, Jeffrey D.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (11) : 1692 - 1699
  • [25] Patient-reported outcomes in a randomized comparison of etanercept and placebo for treatment of psoriatic arthritis
    Mease, P. J.
    Woolley, M.
    Singh, A.
    Tsuji, W.
    Dunn, M.
    Chiou, C. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 535 - 535
  • [26] PATIENT-REPORTED MEDICAL OUTCOMES ACCORDING TO PHYSICIAN TYPE AND REGION
    GLENN, LL
    JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 1995, 85 (06): : 328 - 337
  • [27] Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis
    Gossec, Laure
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E159 - E160
  • [28] Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis
    Mease, Philip J.
    Woolley, J. Michael
    Singh, Amitabh
    Tsuji, Wayne
    Dunn, Meleana
    Chiou, Chiun-Fang
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1221 - 1227
  • [29] Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis
    Proton Rahman
    Iain B. McInnes
    Atul Deodhar
    Georg Schett
    Phillip J. Mease
    May Shawi
    Daniel J. Cua
    Jonathan P. Sherlock
    Alexa P. Kollmeier
    Xie L. Xu
    Shihong Sheng
    Christopher T. Ritchlin
    Dennis McGonagle
    Clinical Rheumatology, 2024, 43 : 1591 - 1604
  • [30] Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials
    Lars-Erik Kristensen
    Dennis McGonagle
    Martin Rudwaleit
    Hideto Kameda
    Peter Adler Würtzen
    Marcus Ngantcha
    Thorsten Holzkämper
    Josef Smolen
    Rheumatology and Therapy, 2025, 12 (2) : 381 - 395